Originally published as JCO Early Release 10.1200/JCO.2006.10.1386 on April 9 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sieniawski, M. Articles by Josting, A. Search for Related Content PubMed PubMed Citation Articles by Sieniawski, M. Articles by Josting, A.

Outcome of Patients Experiencing Progression or Relapse After Primary Treatment With Two Cycles of Chemotherapy and Radiotherapy for Early-Stage Favorable Hodgkin's Lymphoma

Michal Sieniawski, Jeremy Franklin, Lucia Nogova, Jan-Peter Glossmann, Thomas Schober, Hiltrud Nisters-Backes, Volker Diehl, Andreas Josting

From the First Department of Internal Medicine, University Hospital Cologne; and German Hodgkin Study Group, Cologne, Germany

Address reprint requests to Michal Sieniawski, MD, First Department of Internal Medicine, University Hospital Cologne, Kerpener Strasse 62, 50924 Cologne, Germany; e-mail: Michal.Sieniawski{at}ncl.ac.uk

Purpose: To evaluate treatment outcome of patients with early-stage favorable Hodgkin's lymphoma (HL) who experience disease relapse after primary treatment with two cycles of chemotherapy followed by radiotherapy (RT).

Patients and Methods: Of 1,129 patients with early-stage favorable HL enrolled onto the HD7/HD10/HD13 trials of the German Hodgkin Study Group, 42 patients were identified with treatment failure, of whom eight had primary progressive disease, seven had early relapse ( 12 months), and 27 had late relapse (> 12 months). We analyzed this group of patients for risk factors, salvage therapy, and treatment outcome.

Results: The median age was 41 years (range, 19 to 72 years); 24 patients were male, 15 patients had outfield relapse, 13 patients infield relapse, and nine patients outfield and infield relapse. At relapse, 24 patients were treated with conventional salvage chemotherapy, 14 patients were treated with high-dose chemotherapy followed by autologous stem-cell transplantation, and four patients were treated with RT alone. At 36 months median follow-up, freedom from second treatment failure (FF2F) and overall survival (OS) were 52% and 67%, respectively. According to the prognostic score for relapsed HL (duration of first remission, clinical stage, and anemia at relapse), patients with two or three poor prognostic features had a significantly worse outcome compared with patients with none or one of these factors (P < .05 for FF2F and OS).

Conclusion: Relapse after primary treatment with two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine followed by RT is rare. In our analysis, results were influenced by a high treatment-related mortality rate. Additional studies are needed to define the optimal salvage therapy.

published online ahead of print at www.jco.org on April 9, 2007.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.